BEGIN:VCALENDAR
VERSION:2.0
PRODID:Spatie calendar-links
BEGIN:VEVENT
UID:8176c63e31d61103e29b33c6d5924c3c
SUMMARY:Short Communication Session I\n\n
DTSTAMP;TZID=e:20230824T163000
DTSTART;TZID=e:20230824T163000
DTEND;TZID=e:20230824T173000
X-ALT-DESC;FMTTYPE=text/html:Short Communication Session I\n\n\n\nChair(s): T. M. Hauser\, Zurich (CH)\; P. Schmid-Grendelmeier\, Zurich (CH)\n\nPresentations:\n\nAllergen-targeting antibodies for the treatment of peanut and pollen allergies\nReferent(s): <span class="presenting-referent"><u>N. Wuillemin\, Schlieren (CH)</u></span>\; <span class="co-referent">D. Bieli\, Schlieren (CH)\; C. Arena\, Schlieren (CH)\; P. Gasser\, Schlieren (CH)\; S. Götschi\, Schlieren (CH)\; R. Scheibling\, Schlieren (CH)\; T. Ilca\, Schlieren (CH)\; M. Paolucci\, Zurich (CH)\; P. Johansen\, Zurich (CH)\; D. Bouis\, Archamps (FR)\; O. Martin-Rodriguez\, Archamps (FR)\; K. Ho Wang Yin\, Archamps (CH)\; B. Ballmer-Weber\, Zurich (CH)\; A. Köhli\, Zurich (CH)\; T. Sonati\, Schlieren (CH)\; A. Barberis\, Schlieren (CH)\; N. Pengo\, Schlieren (CH)\; T. Hauser\, Zurich (CH)</span>\n\nEvaluation of extracellular vesicles as noninvasive early predictive markers for severe COVID-19\nReferent(s): <span class="presenting-referent"><u>P. A. Martinez Murillo\, Davos (CH)</u></span>\; <span class="co-referent">M. Ravi\, Fribourg (CH)\; K. Eriksson\, Fribourg (CH)\; S. Adapa\, Florida (US)\; O. Schildgen\, Cologne (DE)\; M. L. Merten\, Cologne (DE)\; I. Ghiran\, Boston (US)\; C. Karagiannidis\, Cologne (DE)\; P. Krebs\, Bern (CH)\; D. Kressler\, Fribourg (CH)\; M. Stumpe\, Fribourg (CH)\; R. Jiang\, Florida (US)\; P. Y. Mantel\, Davos (CH)</span>\n\nSafety&nbsp\;and efficacy of a respiratory syncytial virus vaccine (mRNA-1345)\, against a spectrum of symptomatic disease in adults aged &ge\;60 years\nReferent(s): <span class="presenting-referent"><u>G. L. Chen\, Cambridge\, MA (US)</u></span>\; <span class="co-referent">J. Goswami\, Cambridge\, MA (US)\; E. Wilson\, Cambridge\, MA (US)\; S. K. Stoszek\, Cambridge\, MA (US)\; R. Mithani\, Cambridge\, MA (US)\; S. Mehta\, Cambridge\, MA (US)\; A. Kapoor\, Cambridge\, MA (US)\; W. Huang\, Cambridge\, MA (US)\; L. Lan\, Cambridge\, MA (US)\; J. Du\, Cambridge\, MA (US)\; L. El Asmar\, Cambridge\, MA (US)\; C. A. Panozzo\, Cambridge\, MA (US)\; P. Ghaswalla\, Cambridge\, MA (US)\; B. M. Francis\, Cambridge\, MA (US)\; A. K. Simorellis\, Cambridge\, MA (US)\; C. A. Shaw\, Cambridge\, MA (US)\; J. M. Miller\, Cambridge\, MA (US)</span>\n\nCD70 targeting bi-specific Natural Killer cell Engager (BIKE) eliminate acute myeloid leukemia cells\nReferent(s): <span class="presenting-referent"><u>M. Boy\, Bern (CH)</u></span>\; <span class="co-referent">H. Bratschi\, Bern (CH)\; C. Riether\, Bern (CH)\; A. Ochsenbein\, Bern (CH)</span>\n\nInterleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and gatekeeper features\nReferent(s): <span class="presenting-referent"><u>M. E. Raeber\, Zurich (CH)</u></span>\; <span class="co-referent">D. Caspar\, Zurich (CH)\; Y. Zurbuchen\, Zurich (CH)\; N. Guo\, Leiden (NL)\; J. Schmid\, Zurich (CH)\; J. Michler\, Basel (CH)\; U. C. Steiner\, Zurich (CH)\; A. E. Moor\, Basel (CH)\; F. Koning\, Leiden (NL)\; O. Boyman\, Zurich (CH)</span>\n\n
LOCATION:Session Room 1
END:VEVENT
END:VCALENDAR